anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis represents an organ dysfunction resulting from the host's maladjusted response to infection, and can give rise to acute kidney injury (AKI), which significantly increase the morbidity and mortality of septic patients. This study strived for identifying a novel therapeutic strategy for patients with sepsis-induced AKI (SI-AKI). Rat tubular epithelial NRK-52E cells were subjected to lipopolysaccharide (LPS) exposure for induction of in-vitro SI-AKI. The expressions of E1A binding protein p300 (EP300) and methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) in NRK-52E cells were assessed by western blot and qRT-PCR, and their interaction was explored by chromatin immunoprecipitation performed with antibody for H3K27 acetylation (H3K27ac). The effect of them on SI-AKI-associated mitochondrial dysfunction of tubular epithelial cells was investigated using transfection, MTT assay, TUNEL staining, 2',7'-Dichlorodihydrofluorescein diacetate probe assay, Mitosox assay, and JC-1 staining. MTHFD2 and EP300 were upregulated by LPS exposure in NRK-52E cells. LPS increased the acetylation of H3 histone in the MTHFD2 promoter region, and EP300 suppressed the effect of LPS. EP300 ablation inhibited the expression of MTHFD2. MTHFD2 overexpression antagonized LPS-induced viability reduction, apoptosis promotion, reactive oxygen species overproduction, and mitochondrial membrane potential collapse of NRK-52E cells. By contrast, MTHFD2 knockdown and EP300 ablation brought about opposite consequences. Furthermore, MTHFD2 overexpress and EP300 ablation counteracted each other's effect in LPS-exposed NRK-52E cells. EP300-mediated H3 acetylation elevates MTHFD2 expression to reduce mitochondrial dysfunction of tubular epithelial cells in SI-AKI.
The present invention relates to oral bone setting granules and capsules, which is mainly prepared from more than 20 kinds of Chinese herbal medicines, such as ledebouriella root, chrysanthemum, yanhusuo, sappan wood, frankincense, myrrh, etc. through water decoction, leaching filtration, drying and packaging. The medicine of the present invention has the therapeutic effect of blood stasis removal, pain alleviation, swelling elimination, inflammation relief, tissue regeneration promotion, bone setting and muscle thinning, can better realize the purposes of eliminating pain and shortening therapy time, and has no side effect. The present invention is free from weather influence during therapy. Cyclic part fractures do not need functional exercise, and other fractures do not need the methods of plaster splints, operation, etc. The bone setting granules and the capsules have the advantages of simple and convenient medication method, no pain for bone setting, rapid recovery and little expense for patients. The present invention is from the Zhangshi bone setting ancestral method of Chengde through the application and the continuous improvement of a plurality of generations by people, has good curative effect through curing hundred thousands times of fracture patients, and has high popalarity in local parts. Therefore, serious sprains can recover in 1 to 4 days, and large-sized fractures can recover in three therapy courses. Besides, one therapy course has 15 days.
The invention discloses a water-soluble micro powder containing florfenicol and a preparation method thereof. The micro powder is prepared from the following raw materials in percentage by weight: 5 to 10 percent of florfenicol, 2.5 to 2.75 percent of PVPK30, 2.5 to 2.75 percent of SDS and the balance anhydrous glucose. PVPK30, SDS and florfenicol are mixed uniformly, crushed, pass through a 150mesh screen, and then are added with the anhydrous glucose to be mixed uniformly. The micro powder also can be combined with other medicines to prepare water-soluble compound florfenicol micro powder. The grain size of the florfenicol through micro powder treatment is finer and more uniform, so the surface area is increased, the porosity is increased, the absorbability and the solubility are improved, the medicines can be well dispersed and dissolved in gastric juice, the contact area with gastric mucosa is enlarged, so that the medicines can be absorbed by the gastrointestinal tract more easily, thereby greatly improving the bioavailability. The preparation method is more convenient than a coating process, and is more applicable to large-scale production.
Pseudohypoaldosteronism type 1 is a rare congenital autosomal recessive disorder, characterised by failure of receptor response to aldosterone. It is caused by mutation in SCNN1A gene with clinical features like failure to thrive in infancy, hyponatraemia, hyperkalaemia and metabolic acidosis. We present a male infant with seizures, hyperkalaemia and with failure to thrive, diagnosed at day 6 of life. The baby required repeated correction for hyperkalaemia; hence, after ruling out treatable causes for hyperkalaemia, exonerated sequencing was done which showed pathogenic mutation for cystic fibrosis and recessive mutation for pseudohypoaldosteronism. But the child was clinically in favour of pseudohypoaldosteronism. Hence, features of pseudohypoaldosteronism predominate cystic fibrosis; they both may coexist.
A method for treating diabetes mellitus type 2 using the diet with garlic tincture provides for drinking at least 400 mL of the aqueous solution of the garlic tincture prior to each meals with thermally treated dishes. The solution is frozen beforehand to the temperature of -2 °C with the following spontaneous thawing to +18°. Furthermore, the unbaked artichoke should be eaten (at least ) before each meal. The breakfast should be taken in three hours after awakening in the morning but not earlier than at 11 hours. The dinner follows in three hours after the end of the breakfast. The evening meal follows in three hours after the end of the dinner but not later than at 20 hours.
In this crossover trial, the B/A group will receive the placebo (B) and then the test product (A). The product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the placebo product for 7 days, applying the placebo product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the test cream, which will be used for 7 days, applying the topical product to the hands twice a day.
PCT No. PCT/EP87/00026 Sec. 371 Date Sep. 30, 1987 Sec. 102(e) Date Sep. 30, 1987 PCT Filed Jan. 20, 1987 PCT Pub. No. WO87/04616 PCT Pub. Date Aug. 13, 1987.The subject matter of the invention is a composition and a process for improving the condition of hair are improved based on a synergistic combination of glycine with a physiologically compatible aliphatic organic acid which is free of amino groups, particularly citric acid, and a wax and/or oil component, particularly a mixture of petrolatum and fatty alcohols. The combination of glycine, physiologically compatible aliphatic organic acid which is free of amino groups, and wax and/or oil components, which combination has a hair conditioning action, is completely harmless physiologically and can also be used together with anionic surfactants. The compositions, according to the invention, act on the hair so as to disentangle it, smooth the hair surface and improve the feel as well as the ability of the hair to be combed.
Background/Objectives: The Mediterranean diet has been widely suggested to exert significant beneficial effects on endothelial oxidative status and cardiometabolic health. Greek Orthodox monasteries, due to their specific nutritional and sartorial habits, comprise a population thatstrictly adheres to nutritional patterns with restricted eating and a plant-based subset of the Mediterranean diet, often accompanied by profound hypovitaminosis D. Time-restricted eating (TRE) is also adopted bya large part of the general lay Greek population for health-promoting reasons, without restrictions on animal product consumption, as imposed by Orthodox religious fasting. However, the comparative effects of these nutritional patterns on oxidative stress markers remain scarce. Methods: The present study attempted to evaluate the effects of Christian Orthodox fasting (COF) in a group of vitamin D-deficient and overweight Orthodox nuns from Central and Northern Greece compared to the implementation of TRE, a 16:8 dietary regimen (16 h of food abstinence and 8 h of feeding) in a cohort of adult women from the general population from the same region with regard to markers of endothelial oxidative status. A group of 50 women from two Orthodox monasteries in Northern Greece and one group of 50 healthy lay women were included. During the enrollment, a detailed recording of their dietary habits was performed, along with a scientific registry of their demographic and anthropometric characteristics (via bioimpedance). The Orthodox nuns followed a typical Orthodox fasting regimen [daily feeding window (8 a.m.-4 p.m.)], whereas the lay women followed a TRE 16:8 regimen with the same feeding time-window with a recommendation to follow a low-fat diet, without characteristics of the Mediterranean diet. We included a complete biochemical analysis, as well as calciotropic profiles [calcium-Ca, albumin, parathyroid hormone-PTH, and 25-hydroxyvitamin D-25(OH)D] and markers of TAC (total antioxidant capacity), GSH (glutathione),and thiobarbituric acid reactive substances (TBARSs) concentrations as markers of oxidative status. Results: All the groups were compared at the baseline regarding their calcium, PTH, and 25(OH)D concentrations, with no statistically significant differences between the groups apart from higher PTH levels in the nuns due to lower 25(OH)D levels. The Orthodox nuns manifested a lower median GSH compared to the controls (6.0 vs. 7.2, p 0.04) and a higher median TAC (0.92 vs. 0.77, p < 0.001). The TBARS comparisons showed no significant difference between the two groups. No significant associations of oxidative status with 25(OH)D, PTH, and the markers of glucose homeostasis were evident. Conclusions: The results of this small pilot study indicate that both dietary regimens have advantages over the oxidative markers compared to each other, with increased TAC in the group of Orthodox nuns after a 16-week period of COF compared to a 16:8 TRE and increased GSH concentrations in the lay women group. Future randomized trials are required to investigate the superiority or non-inferiority between these dietary patterns in the daily clinical setting.
Developing an injectable hemostatic dressing with shape recovery and high blood absorption ratio for rapid hemostasis in noncompressible hemorrhage maintains a critical clinical challenge. Here, double-network cryogels based on carboxymethyl chitosan, sodium alginate, and methacrylated sodium alginate were prepared by covalent crosslinking and physical crosslinking, and named carboxymethyl chitosan/methacrylated sodium alginate (CM) cryogels. Covalent crosslinking was achieved by methacrylated sodium alginate in the freeze casting process, while physical crosslinking was realized by electrostatic interaction between the amino group of carboxymethyl chitosan and the carboxyl group of sodium alginate. CM cryogels exhibited large water swelling ratios (8167 ± 1062 %), fast blood absorption speed (2974 ± 669 % in 15 s), excellent compressive strength (over 160 kPa for CM100) and shape recovery performance. Compared with gauze and commercial gelatin sponge, better hemostatic capacities were demonstrated for CM cryogel with the minimum blood loss of 40.0 ± 8.9 mg and the lowest hemostasis time of 5.0 ± 2.0 s at hemostasis of rat liver. Made of natural polysaccharides with biocompatibility, hemocompatibility, and cytocompatibility, the CM cryogels exhibit shape recovery and high blood absorption rate, making them promising to be used as an injectable hemostatic dressing for rapid hemostasis in noncompressible hemorrhage.
An extract of Asplenium nidus Linn. for manufacturing a drug or healthy product to treat of prostate diseases is disclosed. The extract of Asplenium nidus Linn. comprises pyropheophorbide a methyl ester (C34H36N4O3), pheophorbide a methyl ester(C35H36N4O5), 1-linleoyl-3-linolenoyl-glycerol (C39H66O5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C53H98O6) and 1,3-dipalmitoyl-sn-glycerol (C35H68O5). The extract of Asplenium nidus Linn. is obtained by using a manufacture method comprising steps of: solvent extracting, using an extract solvent to extract an Asplenium nidus Linn. sample and to obtain an extract, with a w/v ratio between the extract solvent and the Asplenium nidus Linn. sample being 50-60mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d, or their combination to obtain an extract of Asplenium nidus Linn.
BACKGROUND: Quitting smoking is difficult and many people who smoke experience cessation fatigue (CF) as a result of multiple failed attempts. This study examined the association of CF with making and sustaining a smoking quit attempt.
METHODS: Data analysed were 4,139 adults (aged 18 years or older) who smoked daily or weekly and participated in the 2018 and 2020 International Tobacco Control Four Country Smoking and Vaping Surveys (ITC 4CV) conducted in Australia, Canada, England, and the US. CF was assessed at baseline using a single question: "To what extent are you tired of trying to quit smoking?" with response options: "Not at all tired"; "Slightly tired"; "Moderately tired"; "Very tired"; or "Extremely tired". We used binary logistic regression models to test the hypothesis that baseline CF would predict lower odds of both making a quit attempt and sustaining abstinence for a month or longer at follow-up adjusted for socio-demographic and smoking/vaping-related covariates.
RESULTS: Persons who currently smoked and reported at least some CF were more likely to make a quit attempt, but less likely to sustain abstinence for at least one month, than those who reported no CF. These associations were independent of socio-demographic variables, and they did not differ by country.
CONCLUSION: Contrary to expectation, CF was positively associated with making a quit attempt and non-linearly associated with lower rates of sustained abstinence at follow-up. While these findings should be replicated, they suggest that people with CF may benefit from targeted support to remain abstinent after a quit attempt.
Invention applies to the medicine and pharmaceutical industry. The invention aims to increase the efficiency of treatment. The herb mixture consists of the following components in g: alder fruits (Fructus Alni) - 50, oak-tree core (Cortex Quercus) - 40, chamomile flowers (Flores Chamomillae) - 30, tormentil root-stock (Rhizoma Tormentillae) - 20, Lady's Mantle (Herba Alchemillae) - 20. Components of the herb mixture are separately pulverised by a hammer crusher and the fine particles sifted. Components are mixed in a drum mixer until the mixture becomes homogeneous. Consumption of the proposed herb mixture stops the looseness of the bowels and improves the state of health.
The present invention is directed to a method of treating estrogen responsiv e breast cancer in an individual comprising administering to an individual a therapeutically effective estradiol inhibiting amount of interferon gamma (I FN- .gamma.) and/or a tumor necrosis factor (TNF) antagonist and/or an interleuk in- 1 (IL-1) antagonists. The invention is based upon the surprising discovery that IFN-.gamma. and/or a tumor necrosis factor (TNF) antagonist and/or an interleukin-1 (IL-1) antagonists inhibit estradiol production in human adipocytes. This discovery is not only important because it allows for the treatment and/or prevention of estrogen dependent breast cancer using IFN- .gamma., TNF antagonists or IL-1 antagonist each alone or in combination, bu t also because IFN-.gamma. and/or TNF antagonists and/or IL-1 antagonists can be used in conjunction with standard anti-estrogen therapy, e.g., tamoxifen and/or aromatase inhibitor, to result in lower estrogen levels than seen wit h standard anti-estrogen therapy alone. Moreover, the ability to lower estroge n levels by means of the present invention, when combined with standard anti- estrogen therapy, provides an important therapeutic option in that it allows the dose of the anti-estrogen to be reduced, reducing the likelihood of side effects and complications commonly seen with anti-estrogen therapy.
The invention relates to a method of reducing chronic inflammatory pain in a human subject with androgen deficiency symptoms, as defined in the instant invention, comprising transdermally administering a pain-reducing amount of a composition comprising a bioactive androgen to a human subject on a daily basis. The invention further relates to a method of increasing the pain threshold of a human subject having symptoms of androgen deficiency comprising transdermally administering a composition comprising a pain threshold-increasing amount of a bioactive androgen to a human subject with androgen deficiency symptoms on a daily basis. The invention may be used to treat both a female subject and a male subject in order to either alleviate chronic inflammatory pain or to raise the subject's pain threshold. In addition, the invention also relates to increasing the levels of endogenous opioid peptides in a human subject by administering an androgen composition to the subject. The invention also encompasses administration of a composition consisting essentially of an androgen for the treatment of chronic inflammatory pain, and for increasing the pain-threshold in a subject. Chronic inflammatory pain has at least two factors that can predispose a subject to such pain. A subject can have low testosterone, be borderline testosterone-deficient, or be testosterone deficient. If this subject enters a stressor state, chronic inflammatory pain can occur. A subject with normal androgen levels can also enter a stressor state, and chronic inflammatory pain can occur.
Participants who successfully complete the baseline examination visit at the clinical site/unit, will be treated with placebo (2 capsules taken orally) for the duration of the lead-in period which will last up to 3 weeks. Investigators and participants will be blinded to exact duration of each participant-specific lead-in period throughout the study.
Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50<86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of proteins, including histones and transcription factors. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones is associated with a condensed chromatin structure and repression of gene transcription. Inhibition of HDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in an open chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized.
Asthma is a highly prevalent chronic disease that disproportionately impacts African American (AA) women. AA women have poorer asthma-related quality of life and higher rates of asthma exacerbations, healthcare utilization and mortality compared to Caucasian women. Further, AA women are less physically active than any other subgroup of adults, which may help explain the asthma health disparities, found between AA and Caucasian women. Physical inactivity among individuals with asthma is associated with poor asthma control and respiratory function, greater health care utilization, and poorer quality of life. Given the connection between poor asthma outcomes and physical inactivity, addressing physical activity (PA) among sedentary AA women with asthma is imperative. Physical activity demonstrated improvement in asthma outcomes specifically asthma control, quality of life and healthcare utilization. Despite these benefits, fewer than 25% of AA women with asthma engage in regular physical activity. The ACTION intervention: physicAl aCtiviTy In minOrity womeN with asthma is a lifestyle PA intervention refined to be applicable for sedentary AA women with asthma.
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine capsule preparation for treating cervical spondylosis and a preparation method of the traditional Chinese medicine capsule preparation. The traditional Chinese medicine capsule preparation is used for solving the problem that a conventional Chinese patent medicine for treating cervical spondylosis has a poor treatment effect. According to the technical scheme, the preparation method comprises the following steps: soaking raw materials which are radix puerariae, ligusticum wallichii, radix astragali, Chinese angelica, radix paeoniae alba, radix clematidis, eucommia bark, caulis spatholobi, salvia miltiorrhiza, cassia twig, safflower and licorice according to proportions by mass, carrying out heating reflux, settling, filtering, concentrating to obtain a liquid extract, drying, grinding into powder, proportionally adding a dispersing agent and other auxiliary materials, and filling, thus obtaining capsules. The traditional Chinese medicine capsule preparation has the functions of activating blood, dissolving stasis, diminishing inflammation, stopping pain, dispelling wind, eliminating dampness and benefiting liver and kidney. The clinical curative effect observation shows that the traditional Chinese medicine capsule preparation has a good curative effect on various cervical spondylosis, quickly takes effect and can achieve the purpose of treating both symptoms and root causes, and the cervical spondylosis is completely healed and does not relapse. The clinical effective rate and curative rate of the traditional Chinese medicine capsule preparation are higher than those of conventional like products.
The experimental group will receive 1-hour robotic training sessions, 3 times per week for a total of 12 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive the same dosage and schedule (1-hour sessions, 3 times/week, 12 total sessions) of conventional one-on-one therapy from an occupational therapist.
In the usual care group infants usually are not held or contained during gavage feeding. Infants in the usual care group are orally fed at the discretion of the nurses or medical team. Once oral feedings are initiated, infants will be observed twice a week using the computer data acquisition system. Follow up visits will occur at 2,6 and 24 months corrected age.